12:00 AM
Feb 28, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Status

LDP-02: Began Phase II trial

Millennium Pharmaceuticals Inc. (MLNM), Cambridge, Mass.
Product: LDP-02
Business: Autoimmune/Inflammation
Therapeutic category: Antibody, Cell adhesion
Target: Integrin alpha(4)beta(7)

Read the full 83 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >